Clinical Trial Update: SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update investigating SHR-1210 combined with apatinib mesylate as perioperative therapy for hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Apatinib Mesylate (apatinib)
• SHR-1210 (camrelizumab)

Snippet

Sponsor: Zhejiang University | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN